Hualan Biological Engineering, Inc. engages in the research, development, production, and sale of self-produced biological and blood products. Its products include intravenous human immunoglobulin, prothrombin complex, immunoglobulin, coagulation factor VIII and human fibrinogen, rabies immune globulin, hepatitis B human immune globulin, tetanus human immunoglobulin, innovative drugs, and biosimilars. The company was founded on March 30, 1992 and is headquartered in Xinxiang, China.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company